Scleroderma or systemic sclerosis (SSc) is a chronic autoimmune connective with unknown etiology and poorly understood pathogenesis. Like other connective tissue diseases, SSC is more common in females, and the highest incidence is observed in the time frame from the third to the fifth decade. The striking array of autoimmune, vascular and fibrotic changes that develop in almost all patients makes SSc unique among connective tissue diseases. Although no animal model developed for SSc to date fully represents all features of human disease, some animal models that demonstrate features of SSc help to better understand the pathogenesis of the disease and develop new therapeutic options. Well-defined animal model selection is critical to the success of a well-conducted in vivo study. It includes induction methodology as well as a variety of approaches for studying skin fibrosis in these models, such as histopathology, immunohistochemistry, dermal thickness, hydroxyproline content of the skin, and flow cytometry analysis of dermal cells. Monitoring the model during the induction of the SSc mouse model, and determining the timing of treatment initiation is very important in the evaluation of treatment success. For this purpose, in vivo evaluation methods have an important place to observe the realization success of the model during induction in the animal. Evaluating the initial skin thickness of each mouse and the response created as a result of the induction, and showing how much response to the treatment according to the skin thickness at the beginning of the treatment is of critical importance for the success of the treatment. In this review, we aimed to evaluate skin fibrosis and lung involvement in a BLM-induced mouse model and to evaluate the differences between studies